KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

Anant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, Anuj Gupta, Akhil Kapoor, Sujay Srinivas, Omshree Shetty, Poonam Jadhav, Veena Desai, Vanita Noronha, Amit Joshi, Nandini Menon, Vijay M Patil, Bal Krishna Mishra, Bipinesh Sansar, Arpita Singh, Swapnil Patel, Satyendra Narayan Singh, Ipsita Dhal, Kunal Ranjan Vinayak, Vikash Pal, Sarika Mandavkar, Sadhana Kannan, Deepali Chaugule, Rajshree Patil, Manali Parulekar, Chaitali Nashikkar, Suman Kumar Ankathi, Rajiv Kumar Kaushal, Aekta Shah, Prasanth Ganesan, Smita Kayal, Ramesh Ananthakrishnan, Noorzia Syed, Debdeep Samaddar, Venkatesh Kapu, Anokhi Shah, D Kaaviya, R Suganiya, Nirmala Devi Srinivasan, Kumar Prabhash, Vikas Ostwal

JNCI Cancer Spectr 8(4) pkae054

PMID39067037
PMCIDPMC11316615
DOI10.1093/jncics/pkae054
发表日期2024-07-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ). METHODS: This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue. RESULTS: Of the 324 patients randomly assigned between July 2020 and November 2022, 305 patients were evaluable for analysis (FOLFOX/CAPOX: 156; DOF/DOX: 149). With a median follow-up time of 19.2 months (95% Confidence Interval [CI] = 16.5 months to 21.9 months) for the entire cohort, the median OS was 10.1 months (95% CI = 9.2 to 10.9) for FOLFOX/CAPOX and 8.9 months (95% CI = 7.3 to 10.5) for DOF/DOX, and this difference was not statistically significant (P = .70). An increased proportion of grade 3 or grade 4 neutropenia (21% vs 3%; P < .001) and grade 2/3 neuropathy (17% vs 7%; P = .005) was seen in patients receiving DOF/DOX. Genomic profiling revealed a low incidence of microsatellite instability (1%) and a high incidence of BRCA1 (8.4%) and BRCA2 (7.5%) somatic alterations. CONCLUSION: FOLFOX or CAPOX chemotherapy for 6 months remains one of the standards of care in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas, with no additional survival benefit seen with the addition of docetaxel. Genomic profiling of patients revealed a higher than previously known incidence of somatic BRCA alterations, which requires further evaluation.CTRI (Clinical Trial Registry of India: CTRI/2020/03/023944).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。